News und Analysen
![Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research
Illumina, Inc. (NASDAQ: ILMN) is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. Giving back is in
![Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company’s 2020 annual stockholders’ meeting. New to the Board are Ron DeLyons, 58, Managing Member and
![Agilent PD-L1 Assay Receives FDA Approval for Use as a Companion Diagnostic](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Agilent PD-L1 Assay Receives FDA Approval for Use as a Companion Diagnostic
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer
![QIAGEN Announces Publication of Reasoned Position Statement for Proposed Acquisition by Thermo Fisher and Date for Annual General Meeting](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
QIAGEN Announces Publication of Reasoned Position Statement for Proposed Acquisition by Thermo Fisher and Date for Annual General Meeting
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Reasoned Position Statement in response to the Offer Document published by Thermo Fisher Scientific
![QIAGEN gibt Veröffentlichung der begründeten Stellungnahme zum Übernahmeangebot von Thermo Fisher sowie Datum der Jahreshauptversammlung bekannt](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
QIAGEN gibt Veröffentlichung der begründeten Stellungnahme zum Übernahmeangebot von Thermo Fisher sowie Datum der Jahreshauptversammlung bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Veröffentlichung der begründeten Stellungnahme in Reaktion auf die von Thermo Fisher Scientific Inc (NYSE: TMO) früher am
![VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005052/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![NEOVACS : VALIDATION OF THE "RESTARTED" PLAN BY THE PARIS COMMERCIAL COURT](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
NEOVACS : VALIDATION OF THE "RESTARTED" PLAN BY THE PARIS COMMERCIAL COURT
- End of court-ordered receivership proceedings
- Continuation of core research in lupus and allergies
- Creation of a new business investing in BioTechs and MedTechs
- New shareholder (HBR Investment
![Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat
![Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious B
![Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary
![IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results
IMV Inc. (the “Company” or “IMV”) (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
![Novus Therapeutics Reports First Quarter 2020 Financial Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Novus Therapeutics Reports First Quarter 2020 Financial Results
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial
![Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”)
![Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a
![Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will
![Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent
![NanoString to Present at the UBS Global Healthcare Conference](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
NanoString to Present at the UBS Global Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company’s management is scheduled to present
![Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Acadia Healthcare to Participate in the UBS Virtual Global Healthcare Conference and the RBC Capital Markets Global Healthcare Virtual Conference](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Acadia Healthcare to Participate in the UBS Virtual Global Healthcare Conference and the RBC Capital Markets Global Healthcare Virtual Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two upcoming virtual healthcare conferences.
On Tuesday, May 19, 2020, the Company will present
![92. Generalversammlung der Vifor Pharma Gruppe](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
92. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der 92. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt.
Aufgrund der aktuellen Situation und im
![92nd Vifor Pharma Group Annual General Meeting](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
92nd Vifor Pharma Group Annual General Meeting
Regulatory News:
At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
In view of the current situation
![Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three
![Humana Ranks #1 in J.D. Power Commercial Member Health Plan Study – in Florida and Texas](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Humana Ranks #1 in J.D. Power Commercial Member Health Plan Study – in Florida and Texas
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it is ranked #1 in Florida and Texas in the 2020 J.D. Power ranking of Commercial member health plans. Humana has
![Lysogene Announces Presentations at Upcoming Meetings](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Lysogene Announces Presentations at Upcoming Meetings
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the upcoming abstract selected
![Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial